Speculation is building that President Donald Trump may delay the introduction of his 100% tariff rate on pharmaceutical ...
The AI Structural Biology (AISB) consortium was set up earlier this year to fine-tune OpenFold3, which is being developed by ...
As academic researchers experience a worsening funding crunch and pharma companies are increasingly hungry for large, ...
“About a third of women affected by a UTI will go on to have recurrent UTIs. This can happen for several reasons, for ...
Crystalys Therapeutics has emerged from its cocoon with $205 million first-round financing and a potential treatment for gout ...
In another episode of our limited Frontiers Health series of the pharmaphorum podcast, we speak with commercial strategy ...
Post-trial access (PTA) is a mechanism that provides continued access to an investigational medicine to those who benefitted ...
The settlement with New York includes a commitment to repay any taxpayer dollars Indivior received for Opvee, recall all the ...
Sanofi has confirmed it is being investigated by the European Commission for potentially anticompetitive activity in its ...
CD19-targeting UB-VV11 became the first in vivo CAR-T cell therapy to be cleared for human testing by the FDA last year, and ...
The shutdown came after lawmakers failed to reach agreement on proposals from both sides, including a bid by Democrats to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback